UK markets close in 2 hours 50 minutes

Elevation Oncology, Inc. (ELEV)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.9700+0.1400 (+3.66%)
At close: 04:00PM EDT
4.0200 +0.05 (+1.26%)
Pre-market: 08:00AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.8300
Open3.7300
Bid3.9300 x 200
Ask3.9800 x 100
Day's range3.6600 - 3.9700
52-week range0.3630 - 5.8300
Volume447,105
Avg. volume875,954
Market cap216.914M
Beta (5Y monthly)1.54
PE ratio (TTM)N/A
EPS (TTM)-0.8500
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.80
  • PR Newswire

    Elevation Oncology to Present at the Citizens JMP Life Sciences Conference

    Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra, Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024, at 11:30 am ET.

  • PR Newswire

    Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements

    Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended March 31, 2024, and highlighted recent business achievements.

  • PR Newswire

    Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024

    Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical data demonstrating proof-of-concept for its differentiated HER3-ADC program. The data will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, Ca